I’m pleased to share with you Sanofi’s 2022 Annual Pricing Principles report. This is the sixth consecutive edition of this [...]
Preclinical findings showed that tolebrutinib, among the investigational BTK inhibitors tested, had the best combination of brain [...]
Researchers from Harvard University recently found that the Epstein-Barr virus (EBV), which is most known for leading to mononucleosis, is [...]
TG Therapeutics has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational [...]
Consortium of Multiple Sclerosis Centers (CMSC) and Atara Biotherapeutics on Thursday - June 10, 2021 at 7:00 PM - 8:00 PM ET on an [...]
Bristol Myers Squibb is conducting a Phase 3b Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing [...]
#MSVisibility Virtual Concert Thank you for your interest in the first-ever #MSVisibility Virtual Concert, a free event to celebrate and [...]
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the [...]
– 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity [...]
Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy [...]